“For more than 20 years, Biogen Idec has been dedicated to improving the lives of people with MS,” said Alfred Sandrock, M.D., Ph.D., group senior vice president, and chief medical officer at Biogen Idec. “We have a broad portfolio and pipeline of innovative MS medicines, we perform important research that continues to advance our understanding of this disease, and we provide meaningful support services for people living with MS. The breadth of data we are presenting at AAN reinforces our enduring commitment to reducing the impact of MS and other serious neurodegenerative diseases.”
As part of its ongoing commitment to further understand the underlying causes of neurological disease, Biogen Idec is presenting new data to help patients and their healthcare providers make optimal treatment decisions and improve patient outcomes. In addition, data at AAN will include results from studies of its currently marketed products, TECFIDERA® (dimethyl fumarate), TYSABRI® (natalizumab), AVONEX® (interferon beta-1a) and FAMPYRA® (prolonged-release fampridine tablets), as well as findings from the clinical programs of its MS pipeline candidates PLEGRIDY™ (peginterferon beta-1a), daclizumab high-yield process (DAC HYP) and Anti-LINGO-1 (BIIB033).
In addition to data presented at the meeting, Biogen Idec will support the American Brain Foundation’s 2014 Brain Health Fair. On Saturday, April 26 Biogen Idec will help sponsor a free, day-long family event that aims to connect thousands of patients, families and caregivers affected by neurological disease. The Brain Health Fair will offer scientific presentations and discussions, educational activities, and a film festival competition that aims to increase public awareness and understanding of neurological disease. Registration is free at BrainHealthFair.com.
Notable data from Biogen Idec at AAN 2014 in MS and Alzheimer’s disease:
EMERGING APPROACHES TO MS MANAGEMENT:
Do MRI Lesions Predict MS Relapses? – Poster P3.190 – Tuesday, April 29, – 3:00 PM
Multiple Sclerosis Decision Model (MSDM): A Multifactorial Model To Monitor Treatment Response And Disease Course In Relapsing Remitting Multiple Sclerosis – Poster P3.133 - Tuesday, April 29 – 3:00 PM
Epidemiological Study To Identify Factors That Influence Clinical Decision Making In Patients With Relapsing Remitting Multiple Sclerosis (RRMS) After At Least 2 Years Of Treatment With Immunomodulators In Germany (EPIDEM) – Poster P7.243 – Thursday, May 1 – 3:00 PM
TECFIDERA
Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients With Relapsing Forms of Multiple Sclerosis – Poster P2.227 – Tuesday, April 29 – 7:30 AM
Clinical Efficacy of Delayed-Release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients with Highly Active Disease: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies – Poster P3.189 – Tuesday, April 29 – 3:00 PM
Clinical Efficacy of Delayed-Release Dimethyl Fumarate in Minority Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies – Poster P3.171 – Tuesday, April 29 – 3:00 PM
Dimethyl Fumarate Utilizes Nrf2-independent and Nrf2-dependent Pathways for Immune Modulation – Platform S53.006 – Thursday, May 1 – 2:15 PM
TYSABRI
Natalizumab Treatment Improves Walking Speed in MS Patients: A Post Hoc Analysis of AFFIRM – Platform S4.006 – Tuesday, April 29 – 2:15 PM
Comparative Efficacy of Switching to Natalizumab Versus Switching to Interferon-Beta or Glatiramer Acetate after On-Treatment MS Relapse Using Propensity-Matched Registry Data – Poster P3.175 – Tuesday, April 29 – 3:00 PM
Comparison of Switching to Natalizumab Versus Remaining on Interferon-Beta or Glatiramer Acetate after On-Treatment MS Relapse Using Propensity-Matched Registry Data – Poster P7.208 – Thursday, May 1 – 3:00 PM
AVONEX
Prospective Evaluation of Persistence, Treatment Adherence, Quality of Life, and Treatment Satisfaction in Patients Treated with an Intramuscular Interferon Beta-1a Autoinjector in a Real-World Clinical Setting – Poster P7.231 – Thursday, May 1 – 3:00 PM
FAMPYRA
Prolonged-Release Fampridine Treatment and Walking Ability and Balance in Patients with Multiple Sclerosis: Results of the Randomized, Double-Blind MOBILE Study- Data Blitz Presentation 010 – Wednesday, April 30 – 6:42 PM; Poster 010 – Wednesday, April 30 – 6:15 PM
PLEGRIDY
Analysis of 2-year Clinical Efficacy and Safety of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study – Platform S4.005 – Tuesday, April 29 – 2:00 PM
Peginterferon Beta-1a Significantly Increases the Proportion of Patients with Freedom from Measured Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the ADVANCE Study – Platform S4.007 – Tuesday, April 29 – 2:30 PM
Peginterferon Beta-1a May Improve Recovery Following Relapses: Data from the Pivotal Phase 3 ADVANCE Study in Patients with Relapsing-Remitting Multiple Sclerosis – Platform S4.003 – Tuesday, April 29 – 1:30 PM; Poster I7-1.002 – Wednesday, April 30 – 4:30 PM
DACLIZUMAB HIGH-YIELD PROCESS
Decrease in T1 black hole volume over 2 years of daclizumab high-yield process treatment – Poster P3.188 – Tuesday, April 29 – 3:00 PM
Reduction in brain atrophy with extended daclizumab HYP treatment: Results of SELECT and the SELECT extension study – Poster P3.187 – Tuesday, April 29 – 3:00 PM
Anti-LINGO -1
Efficacy and Safety of Anti LINGO-1 for the Treatment of Relapsing Forms of Multiple Sclerosis: Design of the Phase 2 SYNERGY Trial – Poster P3.154, – Tuesday, April 29 – 3:00 PM
BIIB037
Experience in a Phase 1b Clinical Trial – Poster P3.207 – Tuesday, April 29, 2014 – 3:00 PM
Full session details and data presentation listings for the 2014 Annual Meeting can be found through the AAN website https://www.aan.com/conferences/2014-annual-meeting/
Story Source: The above story is based on materials provided by MARKETWATCH
Note: Materials may be edited for content and length
